5-alpha reductase inhibitors use in prostatic disease and beyond.

Chislett B, Chen D, Perera ML, Chung E, Bolton D, Qu LG

DOI: 10.21037/tau-22-690
Published: 2023 Mar 31
Container: Translational andrology and urology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21037/tau-22-690,
  title = {5-alpha reductase inhibitors use in prostatic disease and beyond.},
  author = {Chislett B and Chen D and Perera ML and Chung E and Bolton D and Qu LG},
  year = {2023},
  journal = {Translational andrology and urology},
  doi = {10.21037/tau-22-690},
  url = {https://doi.org/10.21037/tau-22-690}
}

RIS

TY  - JOUR
TI  - 5-alpha reductase inhibitors use in prostatic disease and beyond.
AU  - Chislett B
AU  - Chen D
AU  - Perera ML
AU  - Chung E
AU  - Bolton D
AU  - Qu LG
PY  - 2023
JO  - Translational andrology and urology
DO  - 10.21037/tau-22-690
UR  - https://doi.org/10.21037/tau-22-690
ER  -

APA

B, C., D, C., ML, P., E, C., D, B., & LG, Q. (2023). 5-alpha reductase inhibitors use in prostatic disease and beyond.. Translational andrology and urology. https://doi.org/10.21037/tau-22-690

Source records

pubmed · retrieved 2026-09-25T05:27:53.489Z